Drug Target Review

JULY 24, 2025

From academia to antibody architect JJ’s scientific path began in neurobiology with a PhD followed by a postdoctoral role at the Genome Research Center at Academia Sinica. That shift into translational research changed the direction of his career. He earned his Ph.D. in Molecular Medicine from National Taiwan University.

Immune Response

The Pharma Data

AUGUST 1, 2025

This partnership brings together Altasciences’ extensive expertise in preclinical research and early clinical development with VoxCell’s groundbreaking tissue engineering technology, promising to deliver a more human-relevant, predictive, and efficient drug development paradigm.

Drug Development

Drug Target Review

APRIL 30, 2025

Additionally, AI-driven predictive modelling can shorten the preclinical phase by simulating biological responses, leading to more targeted and efficient clinical trials. By using AI to simulate biological responses, researchers can anticipate how different patient cells will react to therapy, minimising trial-and-error approaches.

Drugs

PPD

JUNE 20, 2025

With the expiration of pirfenidone’s patent exclusivity in 2021, sponsors have renewed their focus on developing new therapies. The emergence of new drugs and treatment strategies has broadened treatment options that are in development and fueled research into urgently needed new therapeutic approaches for IPF.

Clinical Development

Drug Target Review

FEBRUARY 10, 2025

His approach focused on integrating key components of the process: research, clinical, regulatory, and manufacturing into a cohesive, unified system. Ive been involved in therapeutics development for over 25 years, working with small, medium, and large biotech companies.

Therapies

The Pharma Data

JUNE 18, 2025

Pushkal Garg to Lead Unified Research and Development Organization, Signaling Strategic Expansion into Next Phase of RNAi Therapeutics Innovation Alnylam Pharmaceuticals , a global leader in RNA interference (RNAi) therapeutics, has announced the promotion of Pushkal Garg, M.D., He holds a B.A.

RNA

Drug Target Review

JULY 18, 2025

With over two decades of experience in biomedical research, he is leading efforts to translate breakthrough GPCR biology into differentiated therapeutic strategies that can overcome immune resistance and offer new hope to patients with limited treatment options. Preparing for the clinic Preclinical success is just the beginning.

Medical Chemistry

PPD

NOVEMBER 11, 2024

Companies can benefit from solutions such as our Accelerator Drug Development, leveraging the combined strength of Thermo Fisher Scientific’s 360˚ Contract Development and Manufacturing Organization (CDMO) and Contract Research Organization (CRO) services , which provides CDMO, CRO and clinical trial supply chain capabilities that further streamline (..)

Drug Development

The Pharma Data

JUNE 25, 2025

By integrating Regulus’ expertise in microRNA science with its own deep capabilities in clinical development, regulatory affairs, and commercialization, Novartis is well-positioned to accelerate farabursen’s clinical path and potentially bring a first-in-class treatment to ADPKD patients.

RNA

The Pharma Data

JUNE 12, 2025

This design was meant to enable clinician-researchers to gauge the ability of rilzabrutinib to control disease activity after the withdrawal of standard therapy. We look forward to further evaluating rilzabrutinib in subsequent phases of its clinical development.” Fast Track and Orphan Drug Designations from FDA The U.S.

Disease

PPD

JULY 29, 2025

These elongated timelines are contributing to soaring costs, with the average cost of developing a new drug rising to approximately $2.6 For sponsors, the imperative to streamline development processes and improve clinical development speed and efficiency has never been more critical. billion (versus $1-1.5

Clinical Trials

The Pharma Data

JUNE 13, 2025

Director of Lymphoma Research at Sarah Cannon Research Institute and principal study investigator for the trial. Vice President of Early Clinical Development and Translational Research at Johnson & Johnson Innovative Medicine. “As formerly Cellular Biomedicine Group, Inc.).

Therapies

The Pharma Data

JUNE 16, 2025

Importantly, the agreement underscores the opportunity for Teva to leverage data generated by Fosun Pharma in its own ongoing and future clinical programs outside of the licensed territories — a synergy that promises to streamline and accelerate the eventual delivery of this therapy to patients in need across the globe.

Therapies

The Pharma Data

JUNE 26, 2025

a global oncology-focused biopharmaceutical company, delivered a comprehensive update to investors today during its highly anticipated Research and Development (R&D) Day. A Global R&D Footprint Backed by Clinical Execution BeOne’s engine of innovation is supported by a vast and diversified global clinical development network.

Research

PPD

JANUARY 15, 2025

About us The PPD clinical research business of Thermo Fisher Scientific , the world leader in serving science, enables our customers to accelerate innovation and increase drug development productivity. Ready to learn more about how to leverage AI and machine learning to maximize your clinical trial efficiency?

Clinical Trials

PPD

MARCH 11, 2025

While individual rare diseases affect populations that are small in numbers, collectively they impact millions globally, posing significant health and research challenges. Real-world data (RWD) and real-world evidence (RWE) have emerged as transformational tools in addressing these hurdles, advancing rare disease drug development.

Drug Development

Alta Sciences

FEBRUARY 19, 2025

Researchers must characterize the anti-drug-antibody (ADA) response in preclinical and clinical studies and report any ADA-positive samples as a risk-based approach. Regulatory Considerations for Oligonucleotide Drug Development and Safety In 2024, the U.S.

Drug Development

The Pharma Data

JUNE 18, 2025

Dr. Marjorie Green, Senior Vice President and Head of Oncology Global Clinical Development at Merck Research Laboratories, emphasized the significance of this new trial within the broader scope of the ADC’s development.

Trials

Drug Target Review

JUNE 11, 2025

Multimodality however can detect and connect trends (and in future generate content) across different modalities and therefore allows for better interpretability, which builds trust between regulators, researchers and industry stakeholders. Using clinical genomics and AI in drug development to elevate success.

Drugs

The Pharma Data

JUNE 24, 2025

In contrast to a conventional pharma partnership, this large scale and flexible funding agreement enables Revolution Medicines to retain control of the clinical development of daraxonrasib, as well as the ability to capture significant value creation that would result from the successful clinical development and commercialization of its pipeline.”

Drug Development

The Pharma Data

JUNE 23, 2025

This study explored the effects of beginning treatment with lower starting doses of MariTide to improve tolerability while maintaining clinical benefit. Both data sets now provide foundational insight into the design and direction of Amgen’s upcoming Phase 3 MARITIME clinical development program.

Trials

Drug Target Review

MAY 23, 2025

As the biotech sector races to improve the tolerability of these revolutionary treatments, Poolbeg Pharma has a novel solution: an oral therapy, POLB 001, to block the development of CRS, by limiting inflammation without affecting the anti-cancer immune responses that are vital for effective immunotherapies.

Immune Response

The Pharma Data

JUNE 12, 2025

Vice President of Early Clinical Development and Translational Research at Johnson & Johnson Innovative Medicine.

Treatment

The Pharma Data

JUNE 24, 2025

This significant financial infusion is designed to fuel Revolution Medicines’ ambitious clinical development and commercialization plans, with a particular focus on its groundbreaking RAS(ON) inhibitor programs for patients with RAS-addicted cancers.

Clinical Development

PPD

JUNE 17, 2025

These hubs support a geographically distributed remote workforce that provides greater stability and project continuity while offering the global expertise and capabilities needed to bolster clinical development success.

Clinical Development

Drug Target Review

AUGUST 8, 2025

Partnering with experienced contract development and manufacturing organisations (CDMOs) can help developers navigate these complexities, accelerate development timelines, and ensure readiness for scalable, cGMP-compliant manufacturing. 3 As these therapies evolve, so too must the tools and processes used to develop them.

Engineering

DrugBank

JUNE 18, 2025

While these regulations protect public health, they also introduce significant challenges for pharmaceutical researchers. Developing a new drug takes an average of 10–15 years and costs upwards of $2 billion, yet the majority of drug candidates fail before reaching regulatory approval.

Drug Development

The Pharma Data

JUNE 15, 2025

Clinical Development Plans and Future Outlook Intellia’s ongoing Phase 3, randomized, double-blind, placebo-controlled HAELO trial is currently assessing the safety and efficacy of lonvo-z at the 50 mg dose in a larger patient population.

Treatment

The Pharma Data

JUNE 26, 2025

This unmet need has driven the development of alternative pharmacological options, including topical eye drops like MR-141, which aim to improve near vision through non-surgical means. Details of the VEGA-3 Phase 3 Trial The VEGA-3 study is part of Viatris’ broader clinical development program to evaluate MR-141 for presbyopia.

Trials

The Pharma Data

JUNE 24, 2025

Bayer and Tsinghua University Deepen Strategic Alliance to Advance Pharmaceutical Innovation in China Bayer and Tsinghua University (THU), two powerhouses in global pharmaceutical innovation and academic research, have announced a renewed commitment to their long-standing partnership.

Pharma R&D

The Pharma Data

JUNE 25, 2025

Despite ongoing research and improvements in immunosuppressive therapy, there remains no FDA-approved treatment specifically for AMR , leaving clinicians with limited tools to prevent or manage the condition effectively. It arises when the recipient’s immune system produces antibodies that attack the transplanted organ.

FDA

Alta Sciences

NOVEMBER 15, 2024

4 Essential Topics to Cover in Your First CRO Meeting pmjackson Fri, 11/15/2024 - 19:22 Starting a partnership with a contract research organization (CRO) is a sometimes intimidating—yet exciting—first step in your drug development journey. Image thumbnail_Blog_Chad and Lisa_v3.jpg Tags About Altasciences Weight 16

Drug Development

The Pharma Data

JULY 2, 2025

This foundational research effort provided valuable baseline insights into the disease burden and progression of CMS, thereby helping to inform the design and evaluation of ARGX-119’s clinical development program. Peter Ulrichts, Ph.D.,

Clinical Trials

Conversations in Drug Development Trends

JULY 3, 2025

The CRO Perspective From a Contract Research Organization (CRO) specializing in the design and execution of studies for innovative therapies, the REMS requirements have significantly complicated the design and execution of CAR T clinical trials.

Therapies

DrugBank

JULY 14, 2025

  Challenges in Managing Drug-Drug Interactions in Clinical Development Predicting and managing DDI in clinical trials is one of the most complex challenges in drug development. By integrating data from sources like DrugBank, researchers can anticipate potential interactions early in the drug development.

Clinical Development

Conversations in Drug Development Trends

JANUARY 21, 2025

Jayaprakash Kotha, MBBS, PhD, ASCP (SH), Vice President, Bioanalytical Laboratory Satish Kumar, MBB, Head of Process Improvement Continuous Innovation is a Cornerstone of Bioanalysis Approximately 80% of drugs that begin the research process fail to reach approval. What is one contributing factor that sets the 20% that do apart from the rest?

Clinical Trials

BioPharma Drive: Drug Pricing

JUNE 11, 2025

In a research note on Wednesday, RBC Capital Markets analyst Leonid Timashev estimated peak yearly sales of the drug could reach nearly $640 million. Ibtrozi has also shown the ability to help people whose cancer has spread to the brain, a leading cause of disease progression, the company said.

FDA